![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextgreen.png)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextred.png)
Sensitive and Validated HPLC Method for Determination of Paclitaxel in Human Serum
Determination of paclitaxel in human blood sample by HPLC method using carbamazepine as internal standard is described. The absolute recovery of paclitaxel from human serum was >90% and the limit of quantification was 0.05 µg/ml. The intra-day relative standard deviation (RSD) ranged from 1. 02 to 3.73% at 1.0 µg/ml, 1.16 to 5.03% at 10.0 µg/ml and 3.33 to 5.01% at 50.0 µg/ml. The inter-day RSD were 1.03, 2.16 and 1.95% at 1.0, 10.0, 50.0 µg/ml, respectively. The method can be applied to measure the serum concentration of paclitaxel in pharmacokinetic and elution kinetics.
Keywords
Paclitaxel, Human Blood Sample, Serum, HPLC
User
Information
- Heldman A Cheng L, Jenkins G, Heller P, Kim D, Ware M, Nater C, Hruban R, Rezai B, Abella B, Bunge K, Kinsella J, Sollott S, Lakatta E, Brinker J, Hunter W, and Froehlich J (2001) Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 103, 2289–95.
- Kuhn J, Rizzo J, Chang S, Schold C,Spence A, Berger M, Robbins H, Metha M, Bozik M, Fulton D, Rector D and Prodos M (1997) Effect of anticinvulsants (ACs) on the phromacokinetics (PK) and metabolic profile of Paclitaxel. Am. Soc. Clin. Oncol. 16, 224a.
- Kumar N (1981) Taxol-induced Polymerization of Purified Tubulin. J. Biological. Chem. 256, 10435-10441.
- Nannan Panday VR, Meerum Terwot JM and Ten Bokkel Huinink WW (1998) The role of pro drug therapy in the treatment of cancer. Proc. Am. Soc. Clin. Oncol. 17,742a.
- Patton JF, Suzanne J, Fanthony G, Haimworth J, Willent N, Baker, Bechert J, Lacerna L and Howard Buris (2000) Weekly paclitaxel prolongated oral eniluracil/ 5-flurouracil: results of a phase-׀ combination study. Proc. Am. Soc. Clin. Oncol. 19,746a.
- Rinaldi, DA, Lormand N, Brierre J, Cole J, Stagg P, Fontenot F, Buller E and Rainer J (2000) A phase 1 trial of gemcitabine (GEM) and paclitaxel (PAc) in patients with advanced solid tumors, administered every 21 days (LOA-2). Proc. Am. Soc. Clin. Oncol. 19, 848a.
- Schellens JHM, Meeru JM, Bokke HWW, Rosing H, Tellingen O, Swart M, Duchin KL and Beijner JH (1998) Cyclosporin A (CsA) strongly enhances oral bioavailability of paclitaxel (Pac) in cancer patients. Pro. Am. Soc. Clin. Oncol. 17, 717a.
- Schwartz GK, Kaubish A, Saltz L and Lison D (2000) Phase 1 trial of sequential paclitaxel and the cyclin dependent kinase inhibitor flavopiridol. Proc. Am. Soc. Clin. Oncol. 18, 160a.
- Sharma A, Conway WD and Staudinger RM (1994) Reverse-phase highperformance liquid chromatographic determination of taxol in mouse plasma. J. Chromatogr. 655, 315-319.
- Sparreboom A and Van Tellingen O (1998) Preclinical pharmacokinetics of paclitaxel and docetaxel. Anti Cancer Drugs. 8, 1-17.
- Wani M, Taylor H, Wall M, Coggon P and McPhail A (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J.Am. Chem. Soc. 93, 2325–2327.
![](https://i-scholar.in/public/site/images/abstractview.png)
Abstract Views: 374
![](https://i-scholar.in/public/site/images/pdfview.png)
PDF Views: 143